Urs Weber MD (@UrsWeberMD) ranks #22 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 7 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: PAPILLON, LIBRETTO-432, DeLLphi-304. CMS Open Payments lists $1,226 in 2025 general payments.
At a Glance
- 12 posts naming a trial in 2026
- 11 trials discussed by name
- Lung Cancer: US #22 · 7 physicians engaged
- CMS Open Payments lists $1,226 in 2025 general payments.
This Month
What Urs Weber MD has posted in the last 30 days. Updated November 10, 2026.
Tarlatamab produces sustained survival benefits in relapsed-refractory SCLC in long-term follow-up from the DeLLphi-304 trial presented at @myESMO #ESMO26. I’m sounding like a broken record here, but we have to get all patients with SCLC access to tarlatamab. @SclcSMASHERS https://t.co/69idgFy8Nf
SAFFRON provides further evidence for 2 key concepts: 1. Continue osimertinib post-progression. 2. Target MET overexpression. My main concern with this particular approach is patient selection. How many patients have c-MET IHC 3+ >90%? @EGFRResisters @myESMO #ESMO26 https://t.co/YCJKZAZcuD
Who Amplifies Urs Weber MD
Physicians who reposted Urs Weber MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #22 | — | 7 | 12 | Full ranking |
Trials Urs Weber MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| PAPILLON | 2 | #10 of 26 | Sep 14, 2026 |
| LIBRETTO-432 | 2 | #17 of 53 | May 31, 2026 |
| DeLLphi-304 | 1 | #18 of 23 | Oct 26, 2026 |
| SAFFRON | 1 | #18 of 50 | Oct 25, 2026 |
| ARROS-1 | 1 | #15 of 26 | Sep 14, 2026 |
| DESTINY-Lung04 | 1 | #26 of 37 | Sep 14, 2026 |
| NAUTIKA1 (ALK) | 1 | — | Sep 14, 2026 |
| REZILIENT3 | 1 | #23 of 27 | Sep 14, 2026 |
| MDT-BRIDGE | 1 | #15 of 18 | Sep 13, 2026 |
| ADAURA | 1 | #26 of 41 | Sep 13, 2026 |
| MAVERICK (SWOG S1827) | 1 | #29 of 33 | Sep 12, 2026 |
Urs Weber MD on PAPILLON
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon 20 insertion positive NSCLC landscape in general! Important call-outs to the value of crossover, efficacy vs toxicity, and the patient perspective. @IASLC #WCLC26 https://t.co/gVY9hl6IGZ
Congratulations @chulkimMD on an excellent presentation of the 5-year OS update from PAPILLON at @IASLC #WCLC2026! Extensive crossover likely wiped out the OS benefit, but amivantamab is clearly a difference-maker here. The landscape continues to evolve with TKIs coming. https://t.co/m9NUAipaFx
Urs Weber MD on LIBRETTO-432
LIBRETTO-432 presented at #ASCO2026 plenary. Selpercatinib (RET) joins osimertinib (EGFR) and alectinib (ALK) as an effective adjuvant therapy for early stage NSCLC. This is clearly a new standard, but questions about optimal duration of treatment and longterm outcomes remain. https://t.co/v3NyRe8wbB
Excellent discussion of LIBRETTO-432 by @christine_lovly. So many great points made. My favorite: “Precision medicine fails if patients are never tested.” All patients with NSCLC need comprehensive molecular testing, irrespective of stage. #ASCO2026 https://t.co/LNrNcRanHa
Urs Weber MD on DeLLphi-304
Tarlatamab produces sustained survival benefits in relapsed-refractory SCLC in long-term follow-up from the DeLLphi-304 trial presented at @myESMO #ESMO26. I’m sounding like a broken record here, but we have to get all patients with SCLC access to tarlatamab. @SclcSMASHERS https://t.co/69idgFy8Nf
Urs Weber MD on SAFFRON
SAFFRON provides further evidence for 2 key concepts: 1. Continue osimertinib post-progression. 2. Target MET overexpression. My main concern with this particular approach is patient selection. How many patients have c-MET IHC 3+ >90%? @EGFRResisters @myESMO #ESMO26 https://t.co/YCJKZAZcuD
Urs Weber MD on ARROS-1
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive cohort are impressive! I’ve had the privilege of seeing firsthand how well and quickly this drug works in my clinic. Very exciting! https://t.co/R18ggyBB4k
Urs Weber MD on DESTINY-Lung04
Congratulations @JuliaRotow on an excellent presentation of DESTINY-Lung04 at @IASLC #WCLC26! T-Dxd is clearly an active drug in HER2-mutant NSCLC, but the lack of OS benefit raises the question of whether its role is truly in 1L, especially now that we have effective TKIs. https://t.co/iPi6JuJCF4
Urs Weber MD on NAUTIKA1 (ALK)
Primary analysis of periop alectinib in resectable stage IB-IIIB NSCLC (NAUTIKA1) at @IASLC #WCLC26. pCR rate of 19%. 31% down-staging to ypN0. High rates of ctDNA clearance, which correlated with pathologic response. 2-year EFS 90%. Periop TKI might be the way to go. https://t.co/fNmk2VvkBb
Urs Weber MD on REZILIENT3
@LudaBazhenovaMD with an excellent discussion of PAPILLON, REZILIENT-3, and the EGFR exon 20 insertion positive NSCLC landscape in general! Important call-outs to the value of crossover, efficacy vs toxicity, and the patient perspective. @IASLC #WCLC26 https://t.co/gVY9hl6IGZ
Urs Weber MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many positive trials in KRAS mutated NSCLC in the coming years. @KRASKickers @myESMO #ESMO26 https://t.co/DmGmetbUuz
Dose-reduced lorlatinib (50mg or 75mg) works just as well as full-dose lorlatinib (100mg). Don’t be afraid to reduce the dose (or even start at a lower dose) if patients are struggling with or worried about toxicity! @ALKPositiveinc #ASCO2026 https://t.co/H0HVWZrbab
The 7-year OS update from CROWN looks a lot like the 2-and 5-year updates. It’s incredible to see this in a population with advanced metastatic NSCLC. Are we curing some of these “incurable” patients or are we just totally suppressing their disease akin to ART in HIV? #ASCO2026 https://t.co/kJISCHnjLd
As impressive as lorlatinib is in the treatment of ALK+ NSCLC, there’s still room for improvement. Neladalkib can still produce a fair number of responses, including in the brain, post-lorlatinib. Attention patients, this drug can be accessed via an EAP! @ALKPositiveinc #ASCO2026 https://t.co/MVA5f5VUb1
Sticking with the theme, PF’4404, a novel PD-1/VEGF-targeted bispecific antibody, shows efficacy as a 1st line treatment for advanced NSCLC. Unfortunately patients with a PD-L1 expression of 0%, who arguably need new therapies the most, were excluded. #ASCO2026 https://t.co/2WIZ6Q6xHr
Industry Payments
CMS Open Payments · 2025 general payments
$1,226 across 3 payments